Alkermes just showed that an orexin 2 receptor agonist, a class of drug known for regulating wakefulness, can improve ADHD symptoms in adults. If the Phase 2 confirms it, this could be the first genuinely new ADHD mechanism in decades.
Imagine you've been taking melatonin to sleep, and it accidentally made you better at math. That's roughly what just happened in an Alkermes clinical trial, except way more rigorous and far more consequential.
Alkermes just dropped Phase 1b proof-of-concept results for ALKS 7290, a drug that targets the orexin 2 receptor, a piece of brain machinery best known for keeping you awake. The surprise: it meaningfully improved ADHD symptoms in adults. And it might crack open an entirely new way to treat one of the most common psychiatric conditions on the planet.
The Brain's Volume Knob
To understand why this matters, you need to know what orexin actually does. Most people in pharma associate orexin receptors with sleep. The blockbuster insomnia drug suvorexant (Belsomra) works by blocking orexin signaling to help you drift off. Takeda has a late-stage orexin agonist called oveporexton for narcolepsy, a condition where orexin neurons are destroyed.
But orexin's job isn't just flipping a light switch between "asleep" and "awake." Think of it more like the brain's volume knob for paying attention. Orexin signaling feeds into the prefrontal cortex (your brain's air traffic controller), the cholinergic system (which sharpens focus), and the locus coeruleus (which handles alertness). Those are exactly the circuits that go haywire in ADHD.
Alkermes looked at that wiring diagram and asked: what if turning up the orexin signal didn't just wake people up, but made them better at focusing?
Fifty People, Fourteen Days, One Clear Signal
The Phase 1b study enrolled 50 adults with ADHD in a double-blind, placebo-controlled design. Participants took either 20 mg or 50 mg of ALKS 7290 daily for 14 days after washing out of their existing medications.
The primary goal was safety and tolerability, not efficacy. But Alkermes also tracked exploratory measures of ADHD symptom severity using the Adult ADHD Investigator Symptom Rating Scale (AISRS), a standard scoring tool. The results were eye-catching: median reductions of at the lower dose and at the higher dose. For context, that kind of dose-dependent improvement is exactly what you want to see in an early trial. It suggests the drug is actually doing something, and doing more of it at higher doses.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
14 points
19 points
The Clinical Global Impression-Severity scale (a broader measure of how sick someone looks to a clinician) showed the same pattern, with median reductions of 1.0 and 2.0 points at the two doses.
Now, important caveat: the study was not designed to prove statistical significance between treatment and placebo groups. Fifty patients over two weeks is a flashlight, not a floodlight. But what it illuminated was enough for Alkermes to move forward with a larger Phase 2 trial, with results expected in 2027.
Clean Enough to Keep Going
Safety is where early-stage drugs often stumble, especially ones that mess with arousal pathways. If you're cranking up a wakefulness signal, insomnia is the obvious risk. And yes, insomnia was the most common side effect. But the broader safety picture looked reassuring: no serious adverse events were reported, most side effects were mild, and not a single patient on the drug dropped out of the trial. (Two placebo patients did, which is the kind of ironic footnote clinical trialists love.)
Other common side effects included dizziness, constipation, and increased urinary urgency. Manageable stuff, especially for a first-in-class mechanism.
Why Wall Street Is Cautiously Interested
Analysts greeted the data warmly, if not euphorically. Stifel reiterated a Buy rating with a $63 price target, noting that the two-week efficacy numbers looked competitive with Strattera (atomoxetine), the most widely used non-stimulant ADHD drug, and even approached stimulant-like territory seen in some studies. Mizuho held its Outperform rating at $65 but flagged that key opinion leaders warned against reading too much into a small trial.
H.C. Wainwright stayed Neutral, embodying the "show me more data" camp. Fair enough. Proof-of-concept is called that for a reason: it proves the concept, not the drug.
A $16 Billion Market Begging for Something New
ADHD pharmacotherapy is a roughly $16 billion global market in 2026, projected to reach $20 billion by 2033. Stimulants like Adderall and Ritalin still account for about 76% of drug revenue, and they work well for most patients. But "most" isn't "all."
The patients who can't take stimulants, because of anxiety, cardiovascular concerns, substance abuse risk, or intolerable side effects, are stuck with a short list of non-stimulant alternatives. Atomoxetine, guanfacine, clonidine, viloxazine: all useful, none exciting. The newest approved entry is centanafadine (Simtriyo), a triple reuptake inhibitor, which still plays in the same catecholamine sandbox as its predecessors.
An orexin agonist would be something genuinely different. Not another variation on the dopamine/norepinephrine theme, but an entirely new pharmacological class working through arousal, attention, and prefrontal circuits. If it pans out, it could become the first truly novel ADHD mechanism in decades.
Alkermes Is Building an Orexin Empire
ALKS 7290 isn't Alkermes' only orexin bet. The company's lead program, alixorexton, is an orexin 2 agonist currently in Phase 3 trials for narcolepsy and Phase 2 for idiopathic hypersomnia. The strategy is clear: use sleep disorders to validate the platform, then expand into psychiatry, fatigue in multiple sclerosis, Parkinson's disease, and now ADHD.
It's a playbook borrowed from oncology, where companies build a single mechanism and then test it across every indication where the biology makes sense. Alkermes is betting that orexin's role in the brain is broad enough to support a multi-indication franchise.
The next twelve months will tell us whether that bet is genius or hubris. Phase 2 ADHD data in 2027 will be the real test, with a larger patient population, longer treatment duration, and (presumably) enough statistical power to separate drug from placebo convincingly.
The Bottom Line
A drug designed around wakefulness biology just showed it can sharpen attention in ADHD. The data is early, the sample is small, and the caveats are real. But the signal is clean, the mechanism is novel, and the unmet need is enormous.
For the millions of adults who can't or won't take stimulants, Alkermes may have just pointed toward a completely different door. Whether it opens remains to be seen.
Clinical & Regulatory4 min read
The Gene Therapy That Could Save Sight for a Disease With Zero Treatments
Beacon Therapeutics just became the first company to hit a pivotal endpoint in XLRP, a blinding inherited disease with zero approved treatments. Their one-shot gene therapy could rewrite the playbook for patients who've had nothing but a front-row seat to their own vision loss.
